Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Facer

Financiado

Cerrado

The First Cell Culture Platform that Enables Affordable Cell Therapies at a Larg...

The First Cell Culture Platform that Enables Affordable Cell Therapies at a Large Scale Cell therapy has shown promising results for treating and curing a large range of diseases, from cancer to diabetes. The principles of cell therapy are easy to describe: cells (possibly modified) are injected into patients. Cell t... ver más

31/12/2020

EUROYOUTHMH

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

EURO YOUTH MENTAL HEALTH CIC No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-12-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

EUROYOUTHMH

1.44M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

AGLARIS AGLARIS The First Fully automated Bioreactor for Large Scal... 71K€ Cerrado

READCELL System for the efficient and non invasive harvesting and REl... 150K€ Cerrado

SMARTER Smart manufacturing for autologous cell therapies enabled by... 1M€ Cerrado

AUTOSTEM Development of closed scalable and AUTOmated robotic system... 6M€ Cerrado

IcoCell Cell line development platform for SMEs to reduce the length... 2M€ Cerrado

CELLBOX Innovative transport of in culture cell-based materials ensu... 4M€ Cerrado

Duración del proyecto: 21 meses Fecha Inicio: 2019-03-21
Fecha Fin: 2020-12-31

Líder del proyecto

EURO YOUTH MENTAL HEALTH CIC No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cell therapy has shown promising results for treating and curing a large range of diseases, from cancer to diabetes. The principles of cell therapy are easy to describe: cells (possibly modified) are injected into patients. Cell therapy is now a reality in Europe: in August 2018 the first two treatments for patients with blood cancer were approved; more of them are about to successfully conclude the approval path. What hinders the large-scale uptake of cell therapy is its costs: culturing enough cells of high quality requires specialised personnel and infrastructure, which only a few centres can afford. The market asks for a scalable cell culture platform that can produce large quantities of high quality cells at much lower costs than done nowadays. To address this need, we have developed the Facer – the first fully-autonomous cell culture platform. The Facer can manufacture billions of high-quality cells starting from the small quantity (about 500,000 cells) of a tissue biopsy without the need of human intervention, thanks to a unique patented iterative process. Our product is at TRL 7; its performances, in terms of quality and costs, are superior to any competitor commercially available. We have developed the Facer over the course of 5 years thanks to cash investments of over €3 million. In the Phase 2 project we will finalise the product, perform a validation with external partners, prepare the product for CE marking (our product is not a medical device), and find a distributor and a launching customer. We will initially tackle the European market to then expand globally once that the local regulatory barriers are overcome. In 2024, after 5 years from the first sale, our turnover will surpass the €60 million and our EBITDA will be over €36 million. Our innovation can enable affordable cell therapies at a large scale and change the life of millions of patients who suffer from diseases that have been deemed 'incurable' so far.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores